Health Economics and Big Data Analytics - HEBDA is a unique major on the Master in Big Data Science program conducted entirely in English.
The HEBDA program is unique as it combines both Health Economics & Big Data science, which gives you opportunity to acquire the best fit for the future job market shaped by the digital health transformation.
Health Economics is a new but dynamically developing science. It is the discipline of economics applied to the topic of health care. Health Economics provides a set of methods and analytical approaches to study the effectiveness, efficiency and value of health technologies with the ultimate objective of optimal allocation of healthcare resources. According to the available estimates, the annual growth of medical expenses until 2022 will be at the rate almost twice as high as the one observed during the period 2013-2017. It is mainly due to the growing medical needs caused by aging.
More than 20% of global population will be above 60 years old by 2050. On top of it, as many as 14 million health workers will be missing by 2030. Given such enormous challenges, health economists are more and more needed. It is the job of health economics to develop the evidence-based decision-making approaches to allocate limited resources across different patient groups.
The business world is currently undergoing a revolution due to the increasing importance of Big Data, and the healthcare sector is no exception. "The Economist" states, that not oil but data is the most valuable resource of the 21st century. More information on health economics, and big data: here.
According to the Organization for Economic Co-operation and Development (OECD), 2.5 exabytes of data is created every day globally. Of what is stored, 30% is health related. There are already some examples indicating how Big Data analytics can support health economists to meet growing challenges of ageing and scarcity of healthcare workers by providing a new “oil” into the evidence-based decision-making models.
In the upcoming years it is anticipated that there will be a large demand for data researchers and specialists in the healthcare industry. Data scientists with an health economics background will be more and more needed to develop new innovative solutions that help to allocate scarce healthcare resources across different patient groups.
Driven with the passion to health economics, Katarzyna Kolasa has acquired more than 20 years of academic and commercial experience with the pricing & reimbursement challenges of medical technologies. At Bristol Myers Squibb and Lundbeck she was leading Market Access teams in Central Eastern European (CEE) and Nordic Region. She was part of Global and Regional Health Economics & Outcomes Research (HEOR) teams at AstraZeneca and BiogenIdec being based in Sweden and Switzerland respectively. Her practical skills in the field of health economics were developed during six years employment contract at the Kalmar County Council in Sweden as well.
For the last four years, she has been developing experience with the pricing &reimbursement challenges in the field of medical devices. Since 2016, Katarzyna has been representing Straub Medical as Global Market Access Lead being the External Principal Consultant for that Swiss family owned company. Prior to that, Katarzyna was employed as a Senior HEOR Director at GE Healthcare.
She holds a Ph.D. degree in health economics and is an author of more than 40 scientific IF publications in the field of health technology assessment, health economics and pharmacoeconomics. Katarzyna Kolasa reviews manuscripts submitted to such prestigious journals as Health Policy, Value in Health, Expert Review of Pharmacoeconomics & Outcomes Research, International Journal for Equity in Health and International Journal of Technology Assessment.
Her extensive knowledge in the field of health economics was acquired at University of York, University of Lund, and University of Bergen as well as during International Doctoral Courses in Health Economics and Policy organized by the Swiss School of Public Health.
Untill April 2020, Prof. Katarzyna Kolasa has authored more than 40 scientific IF publications and delivered more than 1000 lectures to different groups of students. Prior to Kozminski University, she worked as Adiunct at Warsaw Medical University, Faculty of Pharamcy (2009-2015), Adjunct at Ludwik Rydygier Collegium Medicum in Bydgoszcz (2014-2016). She was a Visiting Lecturer at Łazarski MBA in Healthcare program and College of Pharmacoeconomics, HTA, Marketing and Pharmaceutical Law at the Warsaw School of Businesss.
In 2018, Prof. Kolasa was nominated by the Ministry of Science to represent Poland in the COST Action CA17117, COST Association „Towards an International Network for Evidence-based Research in Clinical Health Research”.
She teaches the application of health economics in the field of digital health at MBA Healthcare Program at Medical University in Lublin and Corvinius University in Budapest as well.
Until April 2020, she has given speeches at more than 40 international conferences. Katarzyna Kolasa is coleader of the course Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements organized annually by ISPOR.
Prof. Katarzyna Kolasa is a chair elect of the Digital Health Special Interest Group at ISPOR as well.
Vladimir (Vlad) Zah, Ph.D. brings 20+ years of Health Economics technology and business experience. Since 2000, in various roles as Health Economist, Project Manager and Chief Investigator, Dr. Zah has implemented more than 170 health economic models and assessments in the phase 2, 3 and 4 settings, across various disease areas, which resulted in over 50 publications.
He also consults and has provided HTA training relating to both medications and medical devices to Ministry of Health, National Insurance Funds or at national congresses in Russia, Turkey, Greece, Egypt, Poland, Czech Republic, Slovakia, Hungary, Croatia, Bosnia & Herzegovina, Slovenia, Former Yugoslav Republic of Macedonia (FYROM), Republic of Srpska, Japan and India.
Vladimir Zah has organized and led Multiple-Criteria Decision Analysis (MCDA) consensus seeking project among representative European countries (Poland, Ukraine, Greece, Austria and Serbia) to identify common set of criteria for: a) rare diseases, b) late stage oncology. This project lasted from 2016 through 2018 and resulted in common criteria presented firstly with pilot data (2016), secondly after adjustments with final data (2017) and with manuscript in production. In addition to, over the years, we have organized many HTA roundtable discussions among different country representatives. Thus, his main focus would be on supporting the consensus development aspects of the project: seeking HTA consensus, collaboration and effective implementation
Katarzyna Piotrowska, MA, is employed as an assistant in the Department of Quantitative Methods and Applications of Computer Science. Her research interests focus on social research methodology, risk taking, economic psychology and statistics. Co-author of the ALK Sustainable Development Index. In the years 2008-2009 she was an intern at the Nobody's Children Foundation. Statistical editor of POLISH SOCIOLOGICAL REVIEW magazine (from 2015). Co-author of monographs, author of chapters in monographs and articles from JCR list. Active participant of national and international conferences.
Axel Mühlbacher is a Professor of Health Economics and Health Care Management at Hochschule Neubrandenbergand adjunct professor in the Duke Department of Population Health Sciences, Duke University (USA). He is a CHPIR Senior Research Fellow in the Center for Health Policy and Inequalities Research at the Duke Global Health Institute.He received his PhD in Economics from the Technical University Berlin, and MSc in Business Administration from Eberhard-Karls Universitat (Tübingen). Past positions of Dr. Mühlbacher include assistant professor at Technische Universitat Berlin and research fellow, German Coordinating Agency of Public Health, Albert-Ludwig Universitat Freiburg. He has also served on behalf of the German Federal Ministry of Health as academic advisor to the steering committee, "Measures to create a new definition of 'requiring care,' and a new uniform instrument of evaluation" for the National Association of Statutory Health Funds.
Dr. Mühlbacher's research experience focuses on methodological advances in decision analysis, operations research, econometrics and choice experiments and their application in the health domain. Recent work includes stated preferences research, empirical research to understand the behavioral aspects of health and problems of multi-criteria decision making to inform the optimal design of policies and regulatory decision making. Dr. Mühlbacher has teaching experience in Health Economics, Health Economic Evaluation,Decision Making Theory, Evaluation of Health Care Innovations and Patient Preferences –Discrete choice experiments.
Dr.Mühlbacher is a member of the International Health Economics Association, International Society for Quality of Life Research (Co-Chair SIG Preference Research), ISPOR Conjoint Analysis Experimental Design Good Research Practice Task Force. He currently also co-chairs the ISPOR Working Group stated preference in European healthcare decision making(Stated Preference Research in the European Union).
Ken Redekop, Ph.D. is an Associate Professor of Health Technology Assessment at the Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, The Netherlands. He is a clinical epidemiologist with more than 20 years of experience in observational research, clinical trial analysis, and medical technology assessment and an author of over 100 papers in the medical literature. Current studies include early-stage cost-effectiveness analyses of medical devices and tests, RCT-based economic evaluations, economic evaluations in the Diagnostics Assessment programme of the National Institute for Health and Clinical Excellence (NICE, UK) and outcomes research studies to determine the effectiveness and cost-effectiveness of expensive medicines in daily practice. Most studies relate to diabetes, cardiovascular disease, and cancer, and most involve modelling and evidence synthesis.
Joanna Leśniowska, PhD - Assistant Professor in the Department of Health Economics and Health Care Management at KU. Her scientific interests include health economics and health care, macroeconomic policy, institutional economics, management in the health sector. She is a member of the International Society for Pharmacoeconomics, and Outcomes Research and Western Economic Association International (from 2014), and the European Association for the Study of Diabetes (from 2015). Author of publications in the field of economics in international journals (also with IF coefficient assigned). Active participant of the conference at the national and international level.
During the establishment of the program, the following partners were included as part of its corporate and public advisory board, so students can be sure that the courses and curriculum prepared meet national and global standards:
Strategic partner of the program:
Substantive Public Partners of the program:
Declared partners of the program:
This program is designed for you, if:
During the course of your studies you will acquire knowledge, skills and social competences, e.g. in the following:
After graduation, you will be able to start your career as specialists in institutions dealing with the organization and financing of health services, as well as enterprises responsible for the production or distribution of health technologies.
Job titles include:
Students have access to multiple study resources allowing them to collect all the necessary information for solving practical business problems as well as to dwell into academic science:
COURSES ON THE HEBDA MAJOR
First year students of the programs conducted in English will be able to obtain a scholarship for one year of 7 500 PLN. The scholarship is provided monthly, as 10 deductions of 750 PLN from the tuition fee amount. More information on how to obtain the scholarship you can find by clicking the above banner.
Polish National Agency for Academic Exchange announced second edition of Scholarship Programme addressed to foreign Master programs applicants. More information and contact details here.
|I year - tuition per semester||II year - tuition per semester|
|Tuition per semester paid in full (PLN)
|Tuition per semester in 5 installments (PLN)
||5 x 2 400
||5 x 2 520
|Tuition per semester paid in full (EUR)
|Tuition per semester in 5 installments (EUR*)
||5 x 560
||5 x 590
|Admission fee: 100
* Exchange rates according to NBP table of 2020-02-03: 1 EUR = 4,301 PLN
PRICES IN PLN ARE APPLIED. If you pay in EURO please note that payments in EUR are recalculated into PLN according to the exchange rate of Millennium Bank based on the day of receipt of payment to the Kozminski University bank account. Check current exchange rate.
Prof. Katarzyna Kolasa
Leader of the Major
Head of Admission Office